iShares大型股10%目标缓冲9月主动型ETF STEN 深 沪
等待开盘 04-10 09:30:00 美东时间
25.64
+0.143
+0.56%
华盛通- 最 高25.64
- 今 开25.36
- 成交量 1.65万股
- 最 低 25.36
- 昨 收 25.4968
- 总市值 3487.04万
- 52周最高 28.97
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 24.29
- 委 比 0.00%
- 总股本 136.00万
- 历史最高 28.97
- 量 比 4.45
- 振 幅 1.10%
- 历史最低 24.29
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Pioneer Minerals Executes Strategic US Tungsten Processing Collaboration
BRIEF-Pioneer Minerals Executes Strategic US Tungsten Processing Collaboration April 7 (Reuters) - Pioneer Minerals Ltd PMM.AX : EXECUTES STRATEGIC US TUNGSTEN PROCESSING COLLABORATION EXECUTES NON-BINDING MOU WITH MINERAL TECHNOLOGIES USA FOR SPRINGFIELD CRITICAL MINERALS PROJECT COLLABORATION TO A
04-07 10:07
UPDATE 1-New BP CEO takes helm pledging consistency, staff note shows
UPDATE 1-New BP CEO takes helm pledging consistency, staff note shows O'Neill pledges clear direction as BP focuses on oil and gas BP has suspended buybacks to prioritise cutting debt, oil and gas investment O'Neill credited with bold moves at Woodside, including major US expansion Updates throughou
04-01 16:16
BRIEF-Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis
BRIEF-Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis Eli Lilly and Co LLY.N : LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) DELIVERED UP TO FOUR YEARS OF DURABLE DISEASE CONTROL FOR PATIENTS WITH MODERATE-TO-SEVE
03-27 21:02
BRIEF-Binghatti Says Construction Operations Remain Fully Operational And On Schedule
BRIEF-Binghatti Says Construction Operations Remain Fully Operational And On Schedule March 25 (Reuters) - BINGHATTI HOLDING: SAYS ITS CONSTRUCTION OPERATIONS REMAIN FULLY OPERATIONAL AND ON SCHEDULE DESPITE HEIGHTENED GEOPOLITICAL TENSIONS CANCELLATION RATES REMAIN LOW, CONSISTENT WITH HISTORICAL L
03-25 13:40
Persistent Systems Updates Exchanges on Investor Meetings, Confirms No New Disclosures
The latest announcement is out from Persistent Systems Limited ( ($IN:PERSISTEN...
03-20 03:25
BRIEF-Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System
BRIEF-Microport Neuroscientific Says FDA Grants Breakthrough Device Designation To Apollo Dream Rapamycin Stent System March 18 (Reuters) - MicroPort NeuroScientific Corp 2172.HK : FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO APOLLO DREAM RAPAMYCIN STENT SYSTEM Further company coverage: 2172.HK ((
03-18 18:30
BREAKINGVIEWS-Global currencies have a rich past and poor future: podcast
BREAKINGVIEWS-Global currencies have a rich past and poor future: podcast The host is a Reuters Breakingviews columnist. The opinions expressed are his own. By Peter Thal Larsen LONDON, March 17 (Reuters Breakingviews) - Follow on Apple or Spotify . Listen on the Reuters app . Read the episode trans
03-17 13:12
Persistent clarifies no new disclosures in Catamaran investor meet
The latest announcement is out from Persistent Systems Limited ( ($IN:PERSISTEN...
03-11 03:54
BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization
BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization March 6 (Reuters) - Allarity Therapeutics Inc ALLR.O : ALLARITY THERAPEUTICS CLOSES $20 MILLION FINANCING TO ACCELERATE THE ADVANCE OF STENOPARIB TOWARD FDA APPR
03-06 21:01
Lexicon posts Q4 net loss of USD 15.5 million (54.0% narrower)
Lexicon posts Q4 net loss of USD 15.5 million (54.0% narrower) Lexicon reported Q4 FY2025 total revenues of USD 5.5 million (USD 4.3 million licensing revenue and USD 1.1 million net product revenue from INPEFA). Q4 R&D expenses were USD 11.3 million (-57.6%) and SG&A expenses were USD 8.8 million (
03-05 19:59
